Go to the list of all blogs
Allana's Avatar
published in Blogs
Sep 25, 2026
ProShares UltraShort Russell2000 (TWM) vs. Direxion Daily Small Cap Bear 3X Shares (TZA): Weighing Inverse Exposure to Small Caps

ProShares UltraShort Russell2000 (TWM) vs. Direxion Daily Small Cap Bear 3X Shares (TZA): Weighing Inverse Exposure to Small Caps

Key Takeaways

  • Both ETFs provide inverse exposure to the Russell 2000 Index, which tracks approximately 2,000 small-capitalization U.S. companies, but they differ in leverage levels and issuer structures.
  • TWM seeks daily results equal to -2x the Russell 2000 Index performance, while TZA targets -3x daily results, resulting in higher volatility and amplified returns (positive or negative) for TZA.
  • Both use derivatives such as swaps and futures for exposure rather than direct stock holdings, leading to zero or minimal traditional equity holdings and synthetic replication methods.
  • Expense ratios stand at 0.95% for TWM (net) and 0.99% for TZA (net), with both classified as non-diversified, leveraged inverse products suited for short-term tactical use.
  • Structural differences include TWM's focus on -2x inverse from ProShares and TZA's -3x inverse from Direxion, affecting risk profiles and suitability for varying market sentiment toward small-cap equities.
  • Liquidity profiles reflect active trading in both, supported by options availability on TWM, though investors should note daily reset mechanisms that can lead to compounding effects over longer periods.

Why These Inverse ETFs Matter for Small-Cap Positioning

ProShares UltraShort Russell2000 (TWM) and Direxion Daily Small Cap Bear 3X Shares (TZA) both aim to deliver inverse performance tied to the Russell 2000 Index. This makes them relevant when investors look to hedge or seek gains from potential drops in U.S. small-cap equities. They do not serve as direct alternatives to long-only small-cap funds but instead provide leveraged strategies for downside protection or tactical bearish views. Comparing them brings out differences in leverage strength and how each is structured within the inverse equity space.

ProShares UltraShort Russell2000 (TWM) at a Glance

ProShares UltraShort Russell2000 (TWM) targets daily results, before fees and expenses, that equal two times the inverse (-2x) of the Russell 2000 Index daily performance. The fund uses synthetic replication via swaps and other derivatives, so its holdings center on these instruments rather than individual equities. Its net expense ratio is 0.95%. As a passive leveraged inverse product from ProShares, TWM resets daily and suits short-term applications, with options trading available to add flexibility.

Direxion Daily Small Cap Bear 3X Shares (TZA) at a Glance

Direxion Daily Small Cap Bear 3X Shares (TZA) targets daily results, before fees and expenses, equal to 300% of the inverse (-3x) of the Russell 2000 Index daily performance. It also relies on derivatives such as swaps, futures, and short positions, keeping a synthetic structure with few traditional holdings. The net expense ratio is 0.99%. Issued by Direxion as a passive leveraged inverse ETF, TZA resets daily and targets tactical use with amplified inverse exposure to small caps.

The Small-Cap Environment and Key Drivers

Both ETFs sit in the U.S. small-cap equity space, benchmarked against the Russell 2000 Index. Factors like interest rate expectations, economic growth signals, and shifts between small- and large-cap sectors shape the setting. Flows into or out of small caps can respond to regulatory changes, earnings seasons, and overall market mood. Volatility tends to rise in small-cap names during economic uncertainty or monetary policy shifts, which is worth monitoring closely.

How Performance and Positioning Compare

Over recent market cycles, TZA's higher leverage has led to sharper moves than TWM when the Russell 2000 Index rises or falls, given the -3x versus -2x daily targets. Performance for both links to small-cap dynamics, including earnings from index constituents and macro elements such as interest rate trends. TZA shows greater sensitivity to short-term volatility swings in small caps, while TWM offers a more measured inverse profile. Daily resets create compounding effects that matter for any holding period beyond a single day, a point I keep in mind when reviewing these vehicles.

Using AI Tools in My Research

I also checked this using Tickeron’s AI Screener to see how these ETFs stack up against others in the leveraged inverse category. It helps filter by technical patterns, volatility, and performance metrics, which streamlines spotting comparable ideas without manual effort. The tool has become a regular part of my process for refining ETF comparisons like this one.

Where the Edge Appears

Based on structural features, cost efficiency, and diversification profile, Tickeron’s AI would currently point to a modest probabilistic edge for ProShares UltraShort Russell2000 (TWM) due to its lower expense ratio and moderated leverage. This may fit better with steadier risk exposure across different small-cap sentiment environments. TZA’s higher leverage provides stronger positioning but comes with increased volatility sensitivity.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TWM, TZA

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


TWM in upward trend: price rose above 50-day moving average on August 28, 2026

TWM moved above its 50-day moving average on August 28, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 37 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 20, 2026. You may want to consider a long position or call options on TWM as a result. In 81 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for TWM just turned positive on August 20, 2026. Looking at past instances where TWM's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.

The 10-day moving average for TWM crossed bullishly above the 50-day moving average on September 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +3.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWM advanced for three days, in 234 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

The Aroon Indicator entered an Uptrend today. In 169 of 192 cases where TWM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.

Bearish Trend Analysis

The 10-day RSI Indicator for TWM moved out of overbought territory on September 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 27 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 54 of 56 cases where TWM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

TWM broke above its upper Bollinger Band on September 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Industry description

The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Russell 2000® Index. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is designed to measure the performance of the small-cap segment of the U.S. markets. Under normal circumstances, the fund will obtain inverse leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
View a ticker or compare two or three
TWM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Inverse Equity
Address
ProShares Trust7501 Wisconsin Avenue,Suite 1000Bethesda
Phone
N/A
Web
www.proshares.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.